Genetic Variation in the PPARA Gene is Associated with Simvastatin-Mediated Cholesterol Reduction in the Rotterdam Study

• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet344(8934) , 1383–1389 (1994).
   PubMed Web of Science ®Google Scholar
• Shepherd J , CobbeSM, FordI et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333(20) , 1301–1307 (1995).
   PubMed Web of Science ®Google Scholar
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N. Engl. J. Med.339(19) , 1349–1357 (1998).
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet360(9326) , 7–22 (2002).
   PubMed Web of Science ®Google Scholar
• Cheng AY , LeiterLA. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Curr. Opin. Cardiol.21(4) , 400–404 (2006).
   PubMed Web of Science ®Google Scholar
• Grundy SM , CleemanJI, MerzCN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110(2) , 227–239 (2004).
   PubMed Web of Science ®Google Scholar
• Davidson MH , MakiKC, PearsonTA et al. Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am. J. Cardiol. 96(4) , 556–563 (2005).
   PubMed Web of Science ®Google Scholar
• Yan AT , YanRT, TanM et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am. J. Med. 119(8) , 676–683 (2006).
   PubMed Web of Science ®Google Scholar
• Mangravite LM , KraussRM. Pharmacogenomics of statin response. Curr. Opin. Lipidol.18(4) , 409–414 (2007).
   PubMed Web of Science ®Google Scholar
• Mangravite LM , WilkeRA, ZhangJ, KraussRM. Pharmacogenomics of statin response. Curr. Opin. Mol. Ther.10(6) , 555–561 (2008).
   PubMedGoogle Scholar
• Shitara Y , SugiyamaY. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug–drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol. Ther.112(1) , 71–105 (2006).
   PubMed Web of Science ®Google Scholar
• Schmitz G , DrobnikW. Pharmacogenomics and pharmacogenetics of cholesterol-lowering therapy. Clin. Chem. Lab. Med.41(4) , 581–589 (2003).
   PubMed Web of Science ®Google Scholar
• Zineh I , JohnsonJA. Pharmacogenetics of chronic cardiovascular drugs: applications and implications. Expert Opin. Pharmacother.7(11) , 1417–1427 (2006).
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ , BackmanJT, NiemiM. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin. Pharmacokinet.47(7) , 463–474 (2008).
   PubMed Web of Science ®Google Scholar
• Vickers S , DuncanCA, VyasKP et al. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab. Dispos.18(4) , 476–483 (1990).
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T , GorhamLM, MaB et al. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab. Dispos.25(10) , 1191–1199 (1997).
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T , MaB, YuN. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br. J. Clin. Pharmacol.56(1) , 120–124 (2003).
   PubMed Web of Science ®Google Scholar
• Wang D , GuoY, WrightonSA, CookeGE, SadeeW. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J.11(4) , 274–286 (2011).
   PubMed Web of Science ®Google Scholar
• Elens L , BeckerML, HaufroidV et al. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Pharmacogenet. Genomics 21(12) , 861–866 (2011).
   PubMed Web of Science ®Google Scholar
• Kajinami K , BrousseauME, OrdovasJM, SchaeferEJ. CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. Am. J. Cardiol.93(1) , 104–107 (2004).
   PubMed Web of Science ®Google Scholar
• Becker ML , VisserLE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy. Pharmacoepidemiol. Drug Saf.19(1) , 75–81 (2010).
   PubMed Web of Science ®Google Scholar
• Kim KA , ParkPW, LeeOJ, KangDK, ParkJY. Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J. Clin. Pharmacol.47(1) , 87–93 (2007).
   PubMed Web of Science ®Google Scholar
• Kivisto KT , NiemiM, SchaeffelerE et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 14(8) , 523–525 (2004).
   PubMedGoogle Scholar
• Kuehl P , ZhangJ, LinY et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27(4) , 383–391 (2001).
   PubMed Web of Science ®Google Scholar
• Miao J , JinY, MarundeRL et al. Association of genotypes of the CYP3A cluster with midazolam disposition in vivo. Pharmacogenomics J. 9(5) , 319–326 (2009).
   PubMed Web of Science ®Google Scholar
• Zeigler-Johnson C , FriebelT, WalkerAH et al. CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. Cancer Res.64(22) , 8461–8467 (2004).
   PubMed Web of Science ®Google Scholar
• Klein K , ThomasM, WinterS et al. PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo. Clin. Pharmacol. Ther. 91(6) , 1044–1052 (2012).
   PubMed Web of Science ®Google Scholar
• Hofman A , GrobbeeDE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur. J. Epidemiol.7(4) , 403–422 (1991).
   PubMed Web of Science ®Google Scholar
• Hofman A , van Duijn CM, Franco OH et al. The Rotterdam Study: 2012 objectives and design update. Eur. J. Epidemiol.26(8) , 657–686 (2011).
   PubMed Web of Science ®Google Scholar
• Miller SA , DykesDD, PoleskyHF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res.16(3) , 1215 (1988).
   PubMed Web of Science ®Google Scholar
• Richards JB , RivadeneiraF, InouyeM et al. Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet 371(9623) , 1505–1512 (2008).
   PubMed Web of Science ®Google Scholar
• Fruchart JC . Peroxisome proliferator-activated receptor-α (PPARα): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis205(1) , 1–8 (2009).
   PubMed Web of Science ®Google Scholar
• Fruchart JC , DuriezP, StaelsB. Peroxisome proliferator-activated receptor-α activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr. Opin. Lipidol.10(3) , 245–257 (1999).
   PubMed Web of Science ®Google Scholar
• Kersten S , DesvergneB, WahliW. Roles of PPARs in health and disease. Nature405(6785) , 421–424 (2000).
   PubMed Web of Science ®Google Scholar
• Shin MJ , KanayaAM, KraussRM. Polymorphisms in the peroxisome proliferator activated receptor α gene are associated with levels of apolipoprotein CIII and triglyceride in African–Americans but not Caucasians. Atherosclerosis198(2) , 313–319 (2008).
   PubMed Web of Science ®Google Scholar
• Reinhard W , StarkK, SedlacekK et al. Association between PPARα gene polymorphisms and myocardial infarction. Clin. Sci. (Lond.) 115(10) , 301–308 (2008).
   PubMed Web of Science ®Google Scholar
• Flavell DM , Pineda Torra I, Jamshidi Y et al. Variation in the PPARα gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects. Diabetologia43(5) , 673–680 (2000).
   PubMed Web of Science ®Google Scholar
• Jamshidi Y , MontgomeryHE, HenseHW et al. Peroxisome proliferator – activated receptor α gene regulates left ventricular growth in response to exercise and hypertension. Circulation 105(8) , 950–955 (2002).
   PubMed Web of Science ®Google Scholar
• Tai ES , DemissieS, CupplesLA et al. Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study. Arterioscler. Thromb. Vasc. Biol. 22(5) , 805–810 (2002).
   PubMed Web of Science ®Google Scholar
• Vohl MC , LepageP, GaudetD et al. Molecular scanning of the human PPARα gene: association of the L162v mutation with hyperapobetalipoproteinemia. J. Lipid Res. 41(6) , 945–952 (2000).
   PubMed Web of Science ®Google Scholar
• Flavell DM , JamshidiY, HaweE et al. Peroxisome proliferator-activated receptor α gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation 105(12) , 1440–1445 (2002).
   PubMed Web of Science ®Google Scholar
• Hu M , MakVW, XiaoY, TomlinsonB. Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia. Pharmacogenomics14(1) , 25–34 (2013).
   PubMed Web of Science ®Google Scholar
• Thomas M , BurkO, KlumppB et al. Direct transcriptional regulation of human hepatic cytochrome P450 3A4 (CYP3A4) by peroxisome proliferator-activated receptor α (PPARα). Mol. Pharmacol. 83(3) , 709–718 (2013).
   PubMed Web of Science ®Google Scholar
• Hansten PD . Possible risks to patients receiving statins combined with other medications. J. Am. Coll. Cardiol.41(3) , 519–520 (2003).
   PubMed Web of Science ®Google Scholar
• Williams D , FeelyJ. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin. Pharmacokinet.41(5) , 343–370 (2002).
   PubMed Web of Science ®Google Scholar
• Teslovich TM , MusunuruK, SmithAV et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466(7307) , 707–713 (2010).
   PubMed Web of Science ®Google Scholar

▪ Website

• Complete ATC index 2010. WHO. Collaborating Centre for Drugs Statistics Methodology. www.whocc.no/atc_ddd_index (Accessed 22September2012)
   Google Scholar